Table 1

Demographic, Clinical, and Laboratory Parameters of HIV-1 Infected Mother-Infant Pairs

Patient
Age
Sex
CD4+ cells/mm3
Length of infection a
Antiviral drug
Clinical Evaluation b

MB
28 yr

509
11 mo
None
Asymptomatic
IB
4.75 mo
M
1942
4.75 mo
None
Asymptomatic, P1A
MC
23 yr

818
1 yr6 mo
None
Asymptomatic
IC
14 mo
F
772
14 mo
ZDV
Symptomatic AIDS;P2A,D1,3,F
MD
31 yr

480
2 yr6 mo
None
Asymptomatic
ID
28 mo
M
46
28 mo
ddCc
Symptomatic AIDS, P2AB,F; failed ZDV therapy
MF
23 yr

692
2 yr10 mo
None
Asymptomatic
IF
1 wk
M
2953
1 wk
ZDV
Asymptomatic,P1A
MH
33 yr

538
5 mo
None
Asymptomatic
IHT1
7 mo
F
3157
7 mo
ACTG152
Hepatosplenomeglay lymphadenopathy
IHT2
7 mo
F
2176
7 mo
ACTG152
Hepatosplenomegaly lymphadenopathy

M: mother; I: infant. aLength of infection: The closest time of infection that we could document was the first positive HIV-1 serology date or the first visit of the patient to the AIDS treatment Center, where all the HIV-1 positive patients were referred to as soon as an HIV-1 test was positive. Therefore, these dates may not reflect the exact dates of infection.

b Evaluation for infants is based on CDC criteria, cddC, Zalcitibine

Sundaravaradan et al. Retrovirology 2005 2:36   doi:10.1186/1742-4690-2-36

Open Data